Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Bank of America

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Bank of America from an “underperform” rating to a “buy” rating in a research report issued on Wednesday,Benzinga reports. The firm currently has a $860.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $627.00. Bank of America‘s price target indicates a potential upside of 10.75% from the stock’s current price.

REGN has been the subject of several other reports. Scotiabank lifted their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Citigroup boosted their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Finally, Truist Financial initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a “buy” rating and a $798.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $790.05.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $776.54 on Wednesday. The firm has a market cap of $81.61 billion, a P/E ratio of 18.60, a PEG ratio of 2.28 and a beta of 0.39. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $792.77. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $729.10 and a 200 day moving average of $623.54.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same quarter last year, the company earned $12.46 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Avior Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 3.1% in the 4th quarter. Avior Wealth Management LLC now owns 1,509 shares of the biopharmaceutical company’s stock worth $1,165,000 after acquiring an additional 46 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Park Avenue Securities LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.1% in the fourth quarter. Park Avenue Securities LLC now owns 1,616 shares of the biopharmaceutical company’s stock worth $1,247,000 after purchasing an additional 49 shares during the period. GK Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $247,000. Finally, Union Bancaire Privee UBP SA raised its position in shares of Regeneron Pharmaceuticals by 672.3% during the 4th quarter. Union Bancaire Privee UBP SA now owns 3,993 shares of the biopharmaceutical company’s stock valued at $3,019,000 after purchasing an additional 3,476 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.